BD Collaborates with Sight Diagnostics to Introduce Parasight Malaria Detection Device in India
NEW DELHI, April 25, 2016 /PRNewswire/ --
BD (Becton, Dickinson and Company) today announced a collaboration with Sight Diagnostics Ltd. (SightDX), to introduce the Parasight Malaria Detection Platform in India. Through this agreement BD will market the Parasight Platform in the Indian diagnostics market, adding to BD's extensive infectious disease diagnostics portfolio. The collaboration will represent the first malaria diagnostics offering from BD.
Varun Khanna, managing director, BD India and South Asia said, "Our collaboration with Sight Diagnostics is aligned with our purpose of advancing the world of health by bringing technology solutions for malaria diagnosis to India. I am confident that this strategic collaboration equips us better than ever before in disease diagnostics and will catalyse BD's role in reducing the global malaria burden."
The SightDX Parasight Malaria Detection Platform uses ground-breaking computer vision technology to analyse blood samples for malarial parasites. The state-of-the-art technology combines innovative software algorithms, specialized optics, and a new sample preparation method, allowing patient samples to be prepared quickly, easily and reliably. The instrument automatically analyses the sample and provides a diagnostic result within only four minutes. The device also provides information on the species of the infecting malarial parasites and provides information that may be used by clinicians to aid in determining the severity of the illness. The diagnostic information is displayed on the instrument's screen and integrates into the facility's lab information management system. The Parasight Malaria Detection Platform has undergone field testing at a number of Indian and international laboratories, during which it demonstrated a high degree of sensitivity and specificity even at very low levels of infection[i].
Yossi Pollak, CEO of SightDX said, "We are excited that Sight Diagnostics and BD are joining forces in the fight against malaria. Our collaboration with BD provides us with an established and experienced partner in the field of infectious disease, and together we can better serve the Indian healthcare market."
The SightDX Parasight Malaria Detection Platform will be BD's first step into the Indian malaria diagnostics market. BD currently markets a wide variety of diagnostic systems in India with numerous offerings in the area of sepsis (blood culture systems), tuberculosis, pathogen identification, and blood cell morphology (flow cytometry systems).
Neeraj Raghuvanshi, business director of Diagnostic Systems at BD added, "Working with Sight Diagnostics now gives us the unique opportunity to closely address the clinical needs of improving the quality of malarial diagnosis in India. In partnership with Sight Diagnostics, we would be able to play a definitive role in early and accurate diagnosis of malaria in India which has been long affected by this tropical disease."
In 2013, approximately 880,000 cases of malaria were reported in India with over 128 million tests performed[ii]. The Parasight Malaria Detection Platform will be marketed in pathology labs and hospitals across India. The technology could also have an application in blood banks, where malaria testing is mandatory on all blood donations.
About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit http://www.bd.com.
About Sight Diagnostics
Sight Diagnostics has developed a ground-breaking platform for blood analysis and infectious disease diagnostics based on its innovations in Computer Vision technology. Sight Diagnostics' platform builds on breakthroughs in sample preparation, biological staining, machine-vision algorithms, and clinical instrumentation, to provide a complete diagnostic solution that is suitable for point-of-care use. Sight Diagnostics' first product, the Parasight Malaria Detection Platform, identifies, enumerates, and speciates malarial parasites more accurately than currently used diagnostic methods. In the future, the technology will detect additional pathogens and blood anomalies. For more information, please visit http://www.sightdx.com
i Based on clinical studies conducted at Apollo Hospital, Chennai, Indian during 2015, and Aga Khan University Hospital, Nairobi, Kenya, in 2016
ii WHO Malaria Report 2014
For more information, please contact:
Josh Turner
Media Relations
[email protected]
Mobile: +972-54-949-6526
Share this article